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Abstract: 
Objective: To evaluate the efficacy of Bevacizumab in central serous chorioretinopathy (CSCR) Methodology: 
It is a randomized control trail. The study was conducted in Ophthalmology department of Allied Hospital, 
Faisalabad and Nishtar Hospital, Multan. From September 2016 to October 2017. Ethical approval was obtained 
from Hospital Ethics committee. Forty six patients took part in this study. Sample was collected using 
probability consecutive sampling technique. Computer software SPSS version 23 was used to analyze the data. 
Frequency and percentage was calculated for the qualitative variables like gender and Chi square test was 
applied to check the significance and association among variables. P value less than and equal to 0.05 was taken 
significant. Results: Forty six patients took part in the study belonging to both genders. There were 58.7% male 
(n=27) and 41.3% females (n=19) when gender distribution was analyzed. Mean and standard deviation for age 
came out to be 47.17±2.13. The baseline value for visual acuity had mean and standard deviation of 42.82±7.91, 
while Mean±S.D of visual acuity after treatment was 57.78±4.33. The difference between the means of visual 
acuity at baseline and after treatment was statistically significant (p=0.001). Similarly mean and standard 
deviation of central macular thickness before and after treatment was 357.89±96.17 and 149.76±30.19 µm 
respectively. There was reduction in the mean of central macular thickness after treatment and the difference 
between the two results was also statistically significant (p=0.001). Conclusion: This study concludes that 
bevacizumab is significantly effectual in the management of CSC. But more research work in the form of 
randomized controlled trails is required to evaluate the effectiveness of intravitreal bevacizumab in this 
condition. 
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Introduction: 
Central serous chorioretinopathy was described as recurrent central syphilitic retinitis for the first time in 1866 
(1)
. Capillarospastic central retinitis, central serous pigment epitheliopathy, central serous retinopathy and central 
angiospastic retinopathy are the other names used for this disease (2). Central serous chorioretinopathy occurs 
most commonly in middle aged men with age ranging between twenty to fifty years (3). Psychological stress and 
people having type A personality are prone to development of central serous chorioretinopathy (4). Other risk 
factors include chronic use of corticosteroids, sympathomimetic agents, some psychopharmacological agents and 
endogenous high levels of corticosteroids. Poor vision and longer period of rehabilitation is associated with 
smoking (5). When serous detachment occurs from choriocapillaris, through retinal pigment epithelium, this 
condition can be defined as central serous chorioretinopathy 6. Choroidal neovascularization, tumors or 
inflammation are among the other causes of retinal pigment epithelium leakage, which need to be ruled out to 
make the final diagnosis of CSC. 
Serous chorioretinopathy has two distinct clinical presentations. Fluorescein angiography has been used to 
classify the cause of central serous chorioretinopathy by one or more particular secluded leak corresponding to 
the retinal pigment epithelium 7. It has been well recognized by now that central serous chorioretinopathy can 
present as diffuse retinal pigment epithelial dysfunction, for instance, decompensated retinal pigment epithelium, 
chronic central serous chorioretinopathy and diffuse retinal pigment epitheliopathy. Diffuse retinal epithelium 
dysfunction is characterized by neurosensory detachment of retinal epithelium, over areas of atrophy of 
epithelium and mottling of the pigment. Broad areas of granular hyper-fluorescence are seen on fluorescein 
angiography, which comprises areas of one or more leaks. 
Most common presentations of central serous chorioretinopathy are metamorphopsia, blurred vision, micropsia 
and mild dyschromatopsia (8). Typical signs found on fundus examination are well demarcated detachment of 
retina at macula. Detachment of pigment epithelial can also occur in variable sizes, single or multiple. Sub 
retinal fluids can be turbid\fibrinous or clear. Sub retinal pigment epithelium space can also be occupied by the 
turbid fluid. Laser photocoagulation, photodynamic therapy and pharmacological agents like acetazolamide, 
mifepristone, propranolol and ketoconazole are different modes of treatment available for central serous 
chorioretinopathy (9). Despite the availability of these treatment options, no modality of these agents has shown 
to reduce the reoccurrence and final visual acuity; instead these treatments only shorten the duration of 
symptoms. 
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Pathophysiology of central serous chorioretinopathy is yet to be clarified. Indocyanine green angiography is the 
modern technique used to try and establish the definite etiology of central serous chorioretinopathy. This 
technique has shown that choroidal permeability changes are the first and foremost reasons which lead to the 
development of central serous chorioretinopathy 10. This theory suggests that, in order to treat this condition, 
target of the treatment should be the choroidal vascular changes. Bevacizumab has anti permeability properties 
and thus thought to be effective in reversing the changes found in central serous chorioretinopathy 11. It is a 
monoclonal antibody against vascular endothelial growth factor. The rationale of our study is as central serous 
chorioretinopathy is disease which leads to eye sight loss, So it should be managed effectively. Our study will 
provide a base for formulating guidelines for central serous chorioretinopathy management in our region and for 
further research on this subject. 
Materials and Methods: 
It is a randomized control trail. Study held in Ophthalmology department of Allied Hospital, Faisalabad and 
Nishtar Hospital, Multan. From September 2016 to October 2017. Ethical approval was obtained from Hospital 
Ethics committee. Forty six patients took part in this study. Sample was collected using probability sampling, 
simple random sampling technique and using reference study by Lim SJ et al (12). Patient aged between 20 and 50 
years, both genders and patients of CSCR as per operational definition were included in this study. Patients with 
previous use of intravitreal bevacizumab, having choroidal neovascularization, more than 21 mmHg of 
intraocular pressure, history of thromboembolism, intraocular inflammation and retinal detachment were 
excluded from this study. All the patients included in this study presented in out-patient department of Mayo 
Hospital Lahore. Informed consent was ensured before including them in the study. 
Name, gender and age were recorded of each patient prior to the initiation of the study. Detailed anterior 
segment slit lamp examination, intraocular pressure measurement, dilated fundal examination and visual acuity 
was recorded at baseline and also at each follow up visit. Pre-op OCT was done and macular thickness was 
documented. Injection was administered into the vitreal cavity using a 27G needle under topical anesthesia. To 
control confounders and thus bias in study result, exclusion criteria were strictly followed. 
The patients were followed at 4 weeks intervals, fundus examination was done and resolution of central serous 
chorioretinopathy was recorded. Optical coherence tomography (OCT) was done at 4 weeks intervals for 3 
months to assess the central macular thickness (CMT). After 4 weeks repeated injections were performed for 
persistent or recurrent central serous chorioretinopathy documented by optical coherence tomography imaging. 
Computer software SPSS version 23 was used to enter and analyze the data obtained from the procedure. 
Frequency and percentage was calculated for the qualitative variables like gender and Chi square test was 
applied to check the significance and association among variables. P value less than and equal to 0.05 was taken 
significant. 
Results: 
A total number of 46 patients took part in the study belonging to both genders. There were 58.7% male (n=27) 
and 41.3% females (n=19) when gender distribution was analyzed. Mean and standard deviation for age came 
out to be 47.17±2.13 (Table 1). The baseline value for visual acuity had mean and standard deviation of 
42.82±7.91, while Mean±S.D of visual acuity after treatment was 57.78±4.33. The results of mean visual acuity 
at baseline were lesser than the mean of visual acuity after treatment. The difference between the means of visual 
acuity at baseline and after treatment was statistically significant (p=0.000). Similarly mean and standard 
deviation of central macular thickness before and after treatment was 357.89±96.17 and 149.76±30.19 µm 
respectively. There was reduction in the mean of central macular thickness after treatment and the difference 
between the two results was also statistically significant (p=0.000) (Table 2). 
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Table. 1 
Demographic characteristics 
Variable Presence 
Gender 
Male 58.7% (n=27) 
Female 41.3% (n=19) 
Age (years) 
47.17±2.13 
 
Table. 2 
Outcome Variables 
Variable Before Treatment After Treatment Test of Sig. 
visual acuity 42.82±7.91 57.78±4.33 t=-10.69, p=0.000 
central macular 
thickness (µm) 
357.89±96.17 149.76±30.19 t=13.74, p=0.000 
 
 
Discussion: 
As we have discussed earlier that there are multiple treatment options available for central serous 
chorioretinopathy like pharmacological agents (propranolol, acetazolamide and ketoconazole), laser 
photocoagulation and photodynamic therapy but in none of these treatment options actually reduce the 
reoccurrence and improve visual acuity of the patients instead only have effect on symptoms of the central 
serous chorioretinopathy. In our study we administered intravitreal bevacizumab and results of the outcome in 
terms of visual acuity and macular thickness were analyzed. The results came out to be very promising and 
showed that intravitreal bevacizumab can be used as an effective treatment option for central serous 
chorioretinopathy. 
The results of our study are in accord to the results of the study done by Schaal KB et al 13 and multiple other 
authors according to whom intravitreal bevacizumab can be regarded as an effective management option in the 
treatment of central serous chorioretinopathy. In another previous study like this study found that all the patients 
who were treated with intravitreal bevacizumab had improvements in fluorescein angiographic leakage, visual 
acuity and resolved neurosensory detachment of retina 14. Results of another study showed that, twelve patients 
treated with intravitreal bevacizumab and eight patients treated with other treatment options had evidence of 
restored morphology at 6 months after treatment (p<0.001). They further described that vision was improved in 
patients who were treated with bevacizumab as compared to the others who were not, and also that central foveal 
thickness was also considerably lower after the treatment in these patients as compared to the patients who did 
not receive intravitreal bevacizumab (297±172 µm and 174±68 µm respectively (P<0.001)). These results clearly 
show that intravitreal bevacizumab although a novel treatment option yet can be used effectively in the treatment 
of selective groups of individuals suffering from chronic, persistent and idiopathic central serous 
chorioretinopathy 15. In acute central serous chorioretinopathy, use of intravitreal bevacizumab may show quick 
improvement by reducing angiographic leakage and by resolving the neurosensory detachment. Studies have 
proved that intravitreal bevacizumab not only improves the condition of chronic central serous chorioretinopathy 
but has equal efficacy in acute central serous chorioretinopathy as well 16. Recurrent cases of central serous 
chorioretinopathy can be effectively managed by the use of intravitreal bevacizumab as shown in a previous 
study. Despite all these studies on the efficacy of bevacizumab as a treatment option, evidence on long term 
efficacy of this antibody is still lacking, but studies show that it is associated with relatively lower risk of 
complications and improves vision and macular thickness 17. 
In contrast to the results of our study a Korean study has stated that in treating patients suffering from acute 
central serous chorioretinopathy, bevacizumab is not much effective as it has no helpful effect in severe settings 
when compared to a study group but it also showed that it had no adverse effects. They emphasized on the fact 
that further investigations are required in order to establish the definitive role of bevacizumab as an option in 
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central serous chorioretinopathy 18. A randomized control trail was done to compare the efficacy of intravitreal 
bevacizumab and photodynamic therapy, which was in favor of the use of photodynamic therapy over 
intravitreal bevacizumab. Central foveal thickness was reduced more in patients who undergone photodynamic 
therapy as compared to the other group which opted for intravitreal bevacizumab 53% and 25% respectively. 
Thus establishing the fact that intravitreal bevacizumab is not as much effective option of treatment as 
photodynamic therapy is. Despite these results, they concluded that intravitreal bevacizumab is safe and effective 
treatment of central serous chorioretinopathy 19. Among the many recent and previous studies, another study 
showed results in contrast to the results of the study just mentioned and their conclusion was that, foveal thinning 
and improvement in vision was more significant in group of patients managed with intravitreal bevacizumab as 
compared to those treated with low fluence photodynamic therapy 20. In another study a one year duration follow 
up was carried out on patients treated with intravitreal bevacizumab and the results were quite satisfactory in 
terms of treatment and outcome of central serous chorioretinopathy and thus concluded that intravitreal 
bevacizumab is an effective treatment for this chronic condition 21. 
Conclusion: 
This study concludes that bevacizumab is significantly effectual in the management of CSC. But more research 
work in the form of randomized controlled trails is required to evaluate the effectiveness of intravitreal 
bevacizumab in this condition. 
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